In recent years, the rapid development of global CGT has brought new hope to patients with rare genetic diseases, refractory chronic diseases and tumors, and has also become the future focus of scientific and technological competition in the entire international field. The "14th Five-Year Plan for Bio-economy Development" issued by the National Development and Reform Commission clearly points out that new technologies such as gene diagnosis and treatment, stem cell therapy, and immune cell therapy should be focused on, and the synergy between industry, university, research and application should be strengthened, and clinical application research and technology product transformation should be accelerated. CGT has been gradually standardized in China, and its market potential is huge. According to reports, the overall global CGT market size will reach US$30.54 billion in 2025, a compound annual growth rate of 71% compared to 2020. China's CGT market size will reach US$2.59 billion in 2025, with a compound annual growth rate of 276%.
While the cell and gene therapy industry is "turbulent" and the market is expanding rapidly, it is even more urgent to deal with the challenges and difficulties it faces. It is mainly manifested in complex regulatory requirements, the standardization and scientificity of clinical translation research need to be improved, complex processes and management processes, immature development of upstream, midstream and downstream supply chains, the application of emerging technologies such as AI, and product commercialization competition. Looking forward to the future, understanding regulatory requirements, promoting clinical transformation, solving production process problems, collaborative innovation of upstream and downstream industries, digitalization of R&D and management processes, product business overseas, and innovative enterprise authorization and cooperation have become the focus of attention in the industry.
The third CGT Asia hosted by Tansi Biotechnology was successfully held in Shanghai from April 3rd to 4th, 2023, and the scene was full of guests. The industry's first "CGT Industry Star" award ceremony held at the same time was recognized and praised by many experts. Welcome everyone in the industry to visit! (For more details: Tansi Biology)
Conference overview:
Conference highlights:
6 thematic and professional technology exhibitions at the 2-day summit, fully focusing on innovative cell and gene therapies
80+ industry leaders share experience insights and application cases
80+ high-quality booths to showcase the latest technologies and solutions
Jointly reported by more than 100 media, one of the most influential CGT industry events in the industry
200+ global cell therapy and gene therapy related companies participated
1500+ domestic and foreign participants
Topic highlights:
Research progress in the direction of cell gene therapy for neurodegenerative diseases
How does cell and gene therapy realize business overseas?
Interpretation of "Technical Guidelines for Benefit-Risk Assessment of New Drugs"
Analysis of the main points of the 2023 new GMP guideline (fourth edition)
Development strategy and prospect of CAR-NK
How to choose a suitable CDMO for a non-self-built production base?
Frontiers of Clinical Research on CGT for Autoimmune Diseases
Opportunities, challenges and development of AI pharmaceutical industry
Digital transformation of clinical research of new tumor drugs in China
Valuation logic and methods of innovative drug companies
Project Roadshow: Clinical Exploration of Mesenchymal Stem Cell Preparations in Rare Diseases and Organ Regeneration
License-in (permission introduction) model strategy and successful case sharing
How to promote innovative therapies step by step
How does cell therapy commercial insurance help products and patients?
Who should attend?
Part of the previous participating companies
Ruijin Hospital, Tsinghua University, Tongji University School of Medicine, Graduate School of Chinese Academy of Social Sciences, Second Affiliated Hospital of An Medical University, Fudan Institute of Biomedical Sciences, Central China Normal University, Jinan University, Jiangsu University School of Medicine, Wuhan University Medical Research Institute, Wuhan Institute of Bioengineering, Xinjiang Medical University, ASC Therapeutics, AstraZeneca, Abbott Biotech, GenScript Biotech, Angpu Biotech, Auscon Biotech, Bangyao Biology, Beihai Kangcheng, Binozy, Iron Biology, Lakeside Biology, Bona West Asia, Santian Pharmaceutical, Shenglin Bio, Panen Bio, Yuanjian Ruckus, Fosun Kate, Gaubb Medical Group, Guite Medicine, Sinopharm Jinqi, Kangwanda Pharmaceutical, Qilu Pharmaceutical, Huadao Bio, Huaxia Yuanbio, Huida Bio, Huier Bio, Jiyuan Gene, Kebei Yuanquan, Longxin Bio, Lepu Bio, Longchang Pharmaceutical, Roche, New Phosphate, Nulunjie Biological, Qilu Pharmaceutical, Merck, Ruizheng Pharmaceuticals, Wisdom Chemicals, Sanofi, Sessel Qing, Sanofi Sheng Guojian, 3SBio, 3SBio, Henlius, Hengrun Dasheng, Huicun Medical, Kazhi Bio, Laifu Medical, Longyao Bio, Longyao Bio, Shanghai Cell Therapy Group, Reindeer Bio, Shanghai Pharmaceutical Group, Innovia, CSPC, Sudi Medicine, Fangde Menda, Xueji Bio, Immobil, Yimofeng, Weisheng Pharmaceutical, Takeda, West Lake Bio, Xingdehan, Xingyiang, Xueji Bio, Reindeer, Wuming Junuo, Chia Tai Tianqing wait...
Some past speakers
Highlights from the previous sessions